Premium
Missing C‐terminal filaggrin expression, NFkappaB activation and hyperproliferation identify the dog as a putative model to study epidermal dysfunction in atopic dermatitis
Author(s) -
Chervet Ludovic,
Galichet Arnaud,
McLean W. H. Irwin,
Chen Huijia,
Suter Maja M.,
Roosje Petra J.,
Müller Eliane J.
Publication year - 2010
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/j.1600-0625.2010.01109.x
Subject(s) - filaggrin , atopic dermatitis , antibody , immunofluorescence , immunology , medicine , biology
Please cite this paper as : Missing C‐terminal filaggrin expression, NFkappaB activation and hyperproliferation identify the dog as a putative model to study epidermal dysfunction in atopic dermatitis. Experimental Dermatology 2010; 19: e343–e346. Abstract: Filaggrin loss‐of‐function mutations resulting in C‐terminal protein truncations are strong predisposing factors in human atopic dermatitis (AD). To assess the possibility of similar truncations in canine AD, an exclusion strategy was designed on 16 control and 18 AD dogs of various breeds. Comparative immunofluorescence microscopy was performed with an antibody raised against the canine filaggrin C‐terminus and a commercial N‐terminal antibody. Concurrent with human AD‐like features such as generalized NFKB activation and hyperproliferation, four distinctive filaggrin expression patterns were indentified in non‐lesional skin. It was found that 10/18 AD dogs exhibited an identical pattern for both antibodies with comparable (category I, 3/18) or reduced (category II, 7/18) expression to that of controls. In contrast, 4/18 dogs displayed aberrant large vesicles revealed by the C‐terminal but not the N‐terminal antibody (category III), while 4/18 showed a control‐like N‐terminal expression but lacked the C‐terminal protein (category IV). The missing C‐terminal filaggrin in category IV strongly points towards loss‐of function mutations in 4/18 (22%) of all AD dogs analysed.